Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	1.28T -21.3%
Revenue (ttm)	1.64T +9.9%
Net Income	195.47B +160.3%
EPS	16,988.64 +160.3%
Shares Out	11.51M
PE Ratio	6.55
Forward PE	7.78
Dividend	600.00 (0.52%)
Ex-Dividend Date	Dec 29, 2025

Volume	8,456
Open	109,500
Previous Close	108,900
Day's Range	109,300 - 112,000
52-Week Range	105,000 - 199,400
Beta	0.03
Analysts	Buy
Price Target	204,444.44 (+83.85%)
Earnings Date	Nov 13, 2026

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,893
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2025, Daewoong Pharmaceutical's revenue was 1.57 trillion, an increase of 10.42% compared to the previous year's 1.42 trillion. Earnings were 195.86 billion, an increase of 691.83%.

Analyst Summary

According to 9 analysts, the average rating for 069620 stock is "Buy." The 12-month stock price target is ₩204,444, which is an increase of 83.85% from the latest price.

Price Target

₩204,444

(83.85% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 17, 2026

Data Sources Report a data error